A W Jabs1, D A Jabs1,2,3, M L Van Natta1, F J Palella4, C L Meinert1. 1. Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. 2. Departments of Ophthalmology, The Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Departments of Medicine, The Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Department of Medicine, The Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
OBJECTIVES: The aim of the study was to evaluate risk factors for mortality, including health care insurance status, among patients with AIDS in the era of modern combination antiretroviral therapy (cART). METHODS: This study was part of the prospective, multicentre, observational Longitudinal Study of the Ocular Complications of AIDS (LSOCA). Patients were classified as having private health care insurance, Medicare, Medicaid, or no insurance. Hazard ratios (HRs) for death were calculated using proportional hazards regression models and staggered entries, anchored to the AIDS diagnosis date. RESULTS: Among 2363 participants with AIDS, 97% were treated with cART. At enrolment, 31% of participants had private insurance, 29% had Medicare, 24% had Medicaid, and 16% were uninsured. Noninfectious, age-related diseases, such as hypertension, diabetes, and renal disease, were more frequent among persons with Medicare than among those with private insurance. Compared with those who were privately insured, mortality was greater among participants with Medicare [adjusted HR (HRadj ) 1.35; 95% confidence interval (CI) 1.08-1.67; P = 0.008]. Among participants with a suppressed HIV viral load, compared with those who were privately insured, HRadj values for mortality were 1.93 (95% CI 1.08-3.44; P = 0.02) for those with Medicare and 2.09 (95% CI 1.02-4.27; P = 0.04) for those with Medicaid. Mortality among initially uninsured participants was not significantly different from that for privately insured participants, but these participants typically obtained ART and insurance during follow-up. Compared with privately insured participants, time-updated HRadj values for mortality were 1.34 (95% CI 1.05-1.70; P = 0.02) for those with Medicare, 1.34 (95% CI 1.01-1.80; P = 0.05) for those with Medicaid, and 1.35 (95% CI 0.97-1.88; P = 0.05) for those who were uninsured. CONCLUSIONS: In persons with AIDS, compared with those with private insurance, those with public insurance had increased mortality, possibly as a result of a greater burden of noninfectious, age-related diseases.
OBJECTIVES: The aim of the study was to evaluate risk factors for mortality, including health care insurance status, among patients with AIDS in the era of modern combination antiretroviral therapy (cART). METHODS: This study was part of the prospective, multicentre, observational Longitudinal Study of the Ocular Complications of AIDS (LSOCA). Patients were classified as having private health care insurance, Medicare, Medicaid, or no insurance. Hazard ratios (HRs) for death were calculated using proportional hazards regression models and staggered entries, anchored to the AIDS diagnosis date. RESULTS: Among 2363 participants with AIDS, 97% were treated with cART. At enrolment, 31% of participants had private insurance, 29% had Medicare, 24% had Medicaid, and 16% were uninsured. Noninfectious, age-related diseases, such as hypertension, diabetes, and renal disease, were more frequent among persons with Medicare than among those with private insurance. Compared with those who were privately insured, mortality was greater among participants with Medicare [adjusted HR (HRadj ) 1.35; 95% confidence interval (CI) 1.08-1.67; P = 0.008]. Among participants with a suppressed HIV viral load, compared with those who were privately insured, HRadj values for mortality were 1.93 (95% CI 1.08-3.44; P = 0.02) for those with Medicare and 2.09 (95% CI 1.02-4.27; P = 0.04) for those with Medicaid. Mortality among initially uninsured participants was not significantly different from that for privately insured participants, but these participants typically obtained ART and insurance during follow-up. Compared with privately insured participants, time-updated HRadj values for mortality were 1.34 (95% CI 1.05-1.70; P = 0.02) for those with Medicare, 1.34 (95% CI 1.01-1.80; P = 0.05) for those with Medicaid, and 1.35 (95% CI 0.97-1.88; P = 0.05) for those who were uninsured. CONCLUSIONS: In persons with AIDS, compared with those with private insurance, those with public insurance had increased mortality, possibly as a result of a greater burden of noninfectious, age-related diseases.
Authors: Douglas A Jabs; Mark L Van Natta; Janet T Holbrook; John H Kempen; Curtis L Meinert; Matthew D Davis Journal: Ophthalmology Date: 2007-01-25 Impact factor: 12.079
Authors: E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo Journal: Ann Intern Med Date: 2001-07-03 Impact factor: 25.391
Authors: Jennifer E Thorne; Douglas A Jabs; John H Kempen; Janet T Holbrook; Charles Nichols; Curtis L Meinert Journal: Ophthalmology Date: 2006-06-12 Impact factor: 12.079
Authors: Milda R Saunders; Ana Catherine Ricardo; Jinsong Chen; Marshall H Chin; James P Lash Journal: BMC Nephrol Date: 2016-03-09 Impact factor: 2.388
Authors: Kelsey B Loeliger; Frederick L Altice; Maria M Ciarleglio; Katherine M Rich; Divya K Chandra; Colleen Gallagher; Mayur M Desai; Jaimie P Meyer Journal: Lancet HIV Date: 2018-09-06 Impact factor: 12.767